Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong
Key facts
- Who runs it
- The University of Hong Kong
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 1,861 people enrolled
- Started
- 7 Oct 2017
- Ended
- 31 Dec 2025
- Type of study
- Interventional, 11 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Standard inactivated influenza vaccine (NH formulation)
- MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
- High-dose inactivated influenza vaccine (NH formulation)
- Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)
- Record updated
- 15 May 2026
Who can take part
- Age
- 65 years to 82 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (5)Hide the full registry criteria
Who can take part
- Adult aged 65-82 years attending ECC and EDC who has not received 2017/18 seasonal influenza vaccine and is willing to receive annual influenza vaccination
Who cannot take part
- Individuals who report medical conditions not suitable to receive inactivated influenza vaccines, such as:; Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine; or to a vaccine component, including egg protein; Moderate or severe acute illness with or without fever after any previous influenza vaccination; or; A history of Guillain-Barré syndrome (GBS) within 6 weeks of previous influenza vaccination
- Individuals who show signs of dementia (do not pass the Mini-cog test under Appendix 1a: Recruitment Screening Log) or significant cognitive impairment and are not competent to give their consent
- Individuals, who report medical conditions not suitable to receive intramuscular injection, such as:; bleeding disorders; habitually taking anticoagulants (with the exception of antiplatelets such as aspirin)
- Individuals who have any medical conditions not suitable to receive inactivated influenza vaccines as determined by a clinician
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study allows to evaluate the strength and duration of immune responses between annual receipt of standard inactivated vaccine and alternative potent vaccines, including annual receipt of adjuvanted inactivated vaccine, annual receipt of high-dose inactivated vaccine, annual receipt of recombinant HA vaccine, and the alternate combinations of the former three vaccines over four years, for identifying improved vaccination strategies for influenza vaccination in older adults in a location experiencing a subtropical pattern in influenza activity.
The 11 groups in the trial
- Standard vaccineExisting treatment, for comparison
Once-annual administration of standard vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Treatment: Standard inactivated influenza vaccine (NH formulation)
- Alternating standard vaccine & adjuvanted vaccineTreatment being tested
Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Treatment: Standard inactivated influenza vaccine (NH formulation) and MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
- Alternating adjuvanted vaccine & standard vaccineTreatment being tested
Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Treatment: Standard inactivated influenza vaccine (NH formulation) and MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
- Alternating standard vaccine and high-dose vaccineTreatment being tested
Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Treatment: Standard inactivated influenza vaccine (NH formulation) and High-dose inactivated influenza vaccine (NH formulation)
- Alternating high-dose vaccine and standard vaccineTreatment being tested
Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Treatment: Standard inactivated influenza vaccine (NH formulation) and High-dose inactivated influenza vaccine (NH formulation)
- Alternating adjuvanted vaccine and high-dose vaccineTreatment being tested
Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Treatment: MF 59 adjuvanted inactivated influenza vaccine (NH formulation) and High-dose inactivated influenza vaccine (NH formulation)
- Alternating high-dose vaccine and adjuvanted vaccineTreatment being tested
Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Treatment: MF 59 adjuvanted inactivated influenza vaccine (NH formulation) and High-dose inactivated influenza vaccine (NH formulation)
- High-dose vaccineTreatment being tested
Once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Treatment: High-dose inactivated influenza vaccine (NH formulation)
- Adjuvanted vaccineTreatment being tested
Once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Treatment: MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
- Recombinant vaccineTreatment being tested
Once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Treatment: Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)
- Alternating recombinant vaccine and adjuvanted vaccineTreatment being tested
Alternating once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Treatment: MF 59 adjuvanted inactivated influenza vaccine (NH formulation) and Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong - a Randomized Controlled Trial
- Publications
- Antineuraminidase Antibody Responses in Older Adults After Consecutive Vaccinations With Enhanced Influenza Vaccines: A Randomized Controlled Trial.The Journal of infectious diseases, 2026
- Enhanced Influenza Vaccines Extend A(H3N2) Antibody Reactivity in Older Adults but Prior Vaccination Effects Persist.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025
- Comparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020
- Comparative Reactogenicity of Enhanced Influenza Vaccines in Older Adults.The Journal of infectious diseases, 2020
- Record updated
- 15 May 2026